Abstract-The effects of endothelin-1 (ET-1) on the production of plasminogen activator inhibitor 1 (PAI-1) and tissue plasminogen activator (t-PA) by human brain-derived endothelial cells in culture were studied. At 100 nmol/L, ET-1 increased PAI-1 production by 88Ϯ6% within 72 hours, and increased PAI-1 mRNA expression within 1 hour of stimulation; there was no significant effect on t-PA production. PAI-1 activity was also examined and found to increase with ET-1 treatment. Suboptimal concentrations of ET-1 and tumor necrosis factor-␣ (TNF-␣) acted synergistically to increase PAI-1 production. ET-1 activated protein kinase C and cAMP-dependent protein kinase pathways within 3 to 5 minutes of treatment, with the peak at 10 minutes. Activation of protein kinase C by phorbol-12-myristate-13-acetate (PMA) resulted in increased PAI-1 production, whereas activation of the cAMP-dependent protein kinase by forskolin or dibutyryl cAMP (dBu-cAMP) significantly decreased PAI-1 production. However, simultaneous activation of protein kinase C by PMA and cAMP-dependent protein kinase by dBu-cAMP only slightly attenuated PMA-induced PAI-1 increase. Inhibition of protein kinase C by GF-109213X abolished the effects of ET-1. These results demonstrate that ET-1 and TNF-␣ function synergistically to induce procoagulant activity of brain endothelial cells in a process that involves a protein kinase C-dependent pathway. (Arterioscler Thromb Vasc Biol. 1999;19:1768-1775.)
I
ncreased levels of endothelin-1 (ET-1) in plasma or cerebrospinal fluid of patients with hypertension, ischemic stroke, and subarachnoid hemorrhage have implicated ET-1 as a mediator of cerebrovascular responses in these disorders. [1] [2] [3] [4] The endothelins (ETs) are a family of potent vasoactive peptides of 21 amino acids in length 5 ; cDNA cloning revealed 3 isopeptides, ET-1 to ET-3. 6 ET has been shown to induce vasoconstriction, 5 but has numerous other biological actions, including bronchoconstriction and hormone secretion, [7] [8] [9] and acts on a variety of cell types, including endothelial cells (EC) and astrocytes. 10 -12 Two distinct ET receptor subtypes, ET A and ET B , have been cloned and sequenced. 13, 14 These receptors contain 7 hydrophobic transmembrane domains common to the superfamily of G-proteincoupled receptors; ET A shows selective activity for ET-1 and ET-2 13 whereas ET B shows nonselective affinity for all 3 isopeptides. 14 EC possess predominantly ET B receptors, which mediate vasodilation. 15, 16 It has been shown that the ET A receptor is expressed on vascular smooth muscle cells and human brain EC, and mediates vasoconstriction. 17, 18 Both receptor subtypes are functionally coupled to phospholipase C via GTP-binding proteins in EC. 19 Signal transduction on ET-1 binding to its receptor may differ among species and tissues and includes activation of phospholipase C and protein kinase C, mobilization of Ca 2ϩ from intracellular stores, and influx of extracellular Ca 2ϩ , as well as inhibition of agonist-stimulated cAMP production. 20 -22 Clot formation and lysis is regulated, in part, by the potent proteolytic enzyme plasmin (see review in Reference 23) . Inactive plasminogen is cleaved and converted to active plasmin by the enzyme tissue plasminogen activator (t-PA.) The t-PA is rapidly inactivated by plasminogen activator inhibitor (PAI). 24 Thus, net fibrinolytic activity in vivo is the result of the balance between the levels of t-PA and PAI. 25, 26 Of several PAI types, PAI-1 appears to be the most important in plasma. 27 Serum PAI-1 levels have been found to be elevated in myocardial infarction, 28 -30 and are associated with an increased risk for thrombotic disease. 31, 32 EC produce t-PA, PAI-1, and PAI-2, 33, 34 which are regulated by factors such as thrombin, histamine, endotoxin, and cytokines, eg, interleukin-1␤ (IL-1␤) and tumor necrosis factor-␣ (TNF-␣). [35] [36] [37] [38] [39] These proinflammatory cytokines act directly on EC by stimulating procoagulation activity. 40 In this study, human brain-derived EC were treated with ET-1 and examined for PAI-1 production. The data here demonstrate that ET-1 upregulates both PAI-1 mRNA and protein levels, as well as PAI-1 activity; and this PAI-1 induction is mediated by a protein kinase C (PK-C)-dependent pathway. Furthermore, TNF-␣ functions synergistically with ET-1 to increase PAI-1 production.
Methods

Reagents
Protein kinase A (PK-A) and PK-C assay kits were purchased from Gibco Life Technologies; cAMP assay kit from DuPont company; [ 32 P]ATP from ICN. Bisindolylmaleimide-GF-109203X (GF; PK-C inhibitor) was purchased from Calbiochem. Phorbol-12-myristate-13-acetate (PMA), dibutyryl cAMP (dBu-cAMP), and forskolin were obtained from Sigma. TNF-␣ was purchased from BoehringerMannheim. ET-1 was obtained from Peninsula Laboratory.
Cell Culture
CNS EC were derived from human brain as previously described. 41 Briefly, brain tissue, obtained after surgery, was digested with a series of collagenase/dispase treatments; cells were isolated on the basis of acetylated-LDL binding and FACS cell sorting. Purity of CNS EC was confirmed by immunocytochemical staining for factor VIII, glial fibrillary acidic protein, and the macrophage marker CD11b, as previously described 41 ; recovery routinely was Ͼ95% of CNS EC. Cells were cultured in RPMI-1640 medium (Gibco Labs), supplemented with 100 ng/mL endothelial cell growth factor Endogro (VECTEC), 2 mmol/L L-glutamine, 10 mmol/L HEPES, 24 mmol/L sodium bicarbonate, 300 U of heparin, 1% penicillin/ streptomycin, and 10% FCS. Only cells from passage 4 to 5 were used in the described experiments; Endogro-free medium was used 24 hours before the initiation of experiments. The inhibitor GF (1 mol/L) was added to cultures 30 minutes before ET-1 treatment.
PAI-1 Production
PAI-1 production was evaluated using the commercially available ELISA kit (American Diagnostics Corp). Briefly, cells were grown in culture to 60% to 70% confluence in 10% FCS. Culture supernatants (100 L) were removed after 24, 48, and 72 hours and evaluated for PAI-1 content. The ELISA determined the total amount of bound and free PAI-1 present. The data for PAI-1 and t-PA are represented as the ratios of the concentrations of PAI-1 or t-PA protein derived from the supernatants of stimulated cell cultures compared with control cultures. The average control value for PAI-1 was 16.3Ϯ3.0 g/mL per 10 6 cells; the average control value for t-PA was 43.5Ϯ2.3 ng/mL per 10 6 cells. Each experiment was performed 3 times, unless otherwise stated.
RNase Protection Assay
The radioactively labeled RNA antisense probe for PAI-1 was prepared using PCR; the ␤-actin template was provided by Ambion. Using the In Vitro Transcription Kit (Ambion), 6 L of 32 P CTP (800 Ci/mmol, 10 mCi/mL; NEN Research) and 2 L each of 10ϫ transcription buffer, T7 polymerase, DTT, and RNAsin were added as suggested by the manufacturer. The reaction was terminated by adding 1 L RNase-free DNase for 1 hour at 37°C. The probes were then extracted using Tris-saturated phenol:cholorform:isoamyl alchol (25:24:1) (GIBCO BRL) and chloroform:isoamyl alcohol sequentially, and then precipitated with ethanol. The radiolabeled RNA pellet was air dried and solubilized with hybridization buffer. RNA was isolated from 2 to 3ϫ10 6 cells per experimental group and prepared according to a modification of the acid phenol method using the Trizol reagent (Life Technologies) as specified by the manufacturer. Total RNA (10 g) together with 6ϫ10 5 cpm of probe was heat denatured at 90°C and then hybridized overnight at 56°C. Subsequently, the samples were treated with the RNase cocktail, followed by proteinase K cocktails, then precipitated using ammonium acetate and ethanol. Air-dried samples were solubilized in 1ϫ loading buffer, denatured at 90°C for 3 minutes, and then placed on ice. The protected fragments were resolved in 5% acrylamide 8 mol/L urea gel; the gel was dried and exposed to Hyper film (Amersham Life Science) at Ϫ70°C. The protected bands were observed for PAI-1 (614 bp) and ␤-actin (320 bp). The differences among the groups were calculated as the ratio of the spectrophotometric densities of the experimental to control groups. The manufacturer's recommended yeast tRNA negative control and a positive control were included in every RNase protection assay (RPA) experiment.
PAI-1 Activity Assay
The PAI-1 activity assay was performed using Pharmacia Coates PAI kit. A fixed amount of t-PA was added in excess to the conditioned media of the treated samples. A portion of t-PA forms an inactive complex with the PAI-1; subsequently, plasminogen was activated to plasmin by residual t-PA in the presence of the stimulator. The amount of plasmin formed is directly proportional to the PAI-1 activity in the conditioned medium. In the presence of chromogenic substrate, the color change was read at 405 nm.
cAMP Assay
The cAMP assays were performed using a kit (DuPont), according to the manufacturer's instructions. Briefly, 2 to 3ϫ10 5 EC were plated in media containing 10% FCS with no Endogro in 60-mm culture dishes 1 to 2 days before the experiment. The cells were grown to near (80% to 90%) confluence; 2 hours before initiating the experiment the growth medium was replaced with medium containing 1% FCS. The cells were treated with different agents for the specified time; the incubation was terminated by replacing the medium with 1 mL of 6% (wt/vol) trichloroacetic acid. The cells were then collected, homogenized with glass dounce homogenizer, and placed on ice for 30 minutes. The cell suspensions were centrifuged at 1500g for 15 minutes at 4°C. The supernatants were collected, and the trichloroacetic acid was removed by washing with water-saturated ether 3 times. Samples were lyophilized and redissolved in cAMP assay buffer (1 mol/L sodium acetate, 0.6% EGTA, 0.2% sodium azide). A portion of the supernatant (100 L) was acetylated to increase sensitivity. The cAMP content of the cells was subsequently measured by RIA (Rianen Assay System). The standard curve was obtained with unlabeled standard cAMP antigen (range, 0.1 to 4 pmol/mL) and a fixed amount of the [
125 I]-labeled antigen reacted with a constant and limiting amount of antibody; a decreasing amount of the labeled antigen is bound to the antibody as the amount of unlabeled standard antigen is increased. These data were used to construct a standard curve from which the values in the samples were determined by interpolation. The data are expressed as meanϮSD. All experiments presented here were performed at least 3 times unless otherwise stated.
PK-A Assay
EC were treated as described for the cAMP assays. The treatments were terminated by rinsing the cells with Dulbecco's PBS and scraping them off with 0.5 mL of extraction buffer (5 mmol/L EDTA, 50 mmol/L Tris, pH 7.5.) The cell suspensions were then homogenized and sedimented (10 000g, 10 minutes). The supernatants were collected for PK-A activity determination. The reaction was initiated by adding 10 L of the lysates to 20 L of reaction buffer; subsequently 10 L of [ 32 P]ATP was added. The PK-A activity was determined as the difference between phosphorylation of a PK-A-specific substrate (Leu-Arg-Arg-Ala-Ser-Leu-Gly, kemptide) with or without a specific peptide PK-A inhibitor, which has an alanine to serine replacement in the consensus sequence Xaa-ArgArg-Xaa-Ser-Xaa and binds to the pseudosubstrate region of the regulatory domain of PK-A. The reaction was allowed to proceed at 30°C for 15 minutes and was terminated by removing a 20-L aliquot to a phosphocellulose filter. Free [ 32 P]ATP was removed by washing the filter twice with both 1% phosphoric acid and water. Substrate phosphorylation was quantified by measuring the radioactivity on the phosphocellulose filters in scintillation fluid (Betafluor). All experiments were repeated at least 3 times and the data presented as meanϮSD.
PK-C Assay
EC were treated as described in the previous sections. The PK-C assays were performed using PK-C assay kits obtained from Gibco. Briefly, the experimental treatments were terminated by replacing the medium with the cell extraction buffer (20 mmol/L Tris, 0.5 mmol/L EDTA, 0.5 mmol/L EGTA, and 25 g/mL each aprotinin and leupeptin, pH 7.5) at room temperature. The cells were then homogenized with a precooled dounce homogenizer, and the cytosol and membrane fractions were separated by centrifugation (10 000g, 30 minutes, 4°C). The supernatants were collected as the cytosol fraction. The pellets were resuspended in 0.5 mL of extraction buffer with the detergent (1% NP-40). Membrane fractions were obtained by centrifugation (10 000g, 10 minutes, 4°C) and collecting the supernatants. PK-C in both membrane and cytosol fractions was partially purified by ion exchange chromatography (DE-52 cellulose column). The determinations of PK-C activity in the cytosol and membrane fractions were performed according to the manufacturer's instructions. The specific PK-C substrate was a synthetic peptide from myelin basic protein (amino acids 4 to 14) with an acetylated N-terminal glutamine, and the specific inhibitor was a peptide (amino acids 19 to 36), derived from the same protein, that binds to the pseudosubstrate region of the regulatory domain. The specific PK-C activity was determined as the difference between phosphorylation of the specific PK-C substrate in the absence or presence of the specific PK-C inhibitor. The data are presented as ratios of the membrane and the total (cytosolϩmembrane) PK-C activities.
Results
ET-1 Upregulates PAI-1 Production by CNS EC
To test the hypothesis that ET-1 directly affects hemostasis, CNS EC were exposed to ET-1 at concentrations of 30 and 100 nmol/L for 72 hours and tested for PAI-1 production with ELISA. The results show that ET-1 significantly (PϽ0.02) increased PAI-1 production in a dose-dependent manner ( Figure 1A ). To determine whether the observed increase represented an upregulation in PAI-1 mRNA expression, RPA was performed. The results ( Figure 1B ) demonstrated that ET-1 upregulated PAI-1 mRNA by 80% after 1 hour of ET-1 treatment; this level was maintained at 3 and 6 hours, and then returned to baseline 24 hours after stimulation. To determine whether t-PA production was also altered by ET-1, culture supernatants were treated as described above and examined for t-PA with ELISA ( Figure 1C) . The results showed that t-PA was not affected by ET-1 at the optimal concentration used (100 nmol/L) ( Figure 1C ). The proinflammatory cytokine TNF-␣, tested at an optimal concentration (10 ng/mL) alone or in the presence of ET-1, also did not alter the t-PA response.
To determine whether ET-1-treated CNS EC also exhibited an increase in PAI-1 activity, supernatant from 72-hour ET-1-treated cultures was examined for PAI-1 activity. The results in Figure 2 demonstrated that ET-1 increased PAI-1 activity by 63Ϯ7%, whereas TNF-␣ induced a 48Ϯ2% increase compared with untreated cultures (PϽ0.02.) These data represent 1 of 3 similar experiments; each experiment was performed in triplicate.
Experiments were performed to determine whether TNF-␣ augmented the effects of ET-1 on PAI-1 production. The results in Figure 3 demonstrated that the addition of a suboptimal concentration of TNF-␣ (30 pg/mL) to a suboptimal dose of ET-1 (30 nmol/L) increased PAI-1 production by 92Ϯ16%, as compared with 35Ϯ12% with ET-1 alone. This level of PAI-1 production was comparable in magnitude with the maximal effects observed with optimal concentration of TNF-␣ (10 ng/mL) (Figure 3 ).
ET-1 Increases PK-A Activity in CNS EC
We next investigated which signal transduction mechanism was involved in ET-1-induced PAI-1 production. Treatment of CNS EC with ET-1 for 10 minutes resulted in a concentration-dependent increase in PK-A activity (Figure 4) . The effect was significant at 10 nmol/L ET-1, with a maximal 5-fold activation reached at 100 nmol/L ET-1 (Figure 4) . The time dependence of PK-A activity in the presence of 100 nmol/L ET-1 is given in Figure 5 . A significant activation of PK-A by ET-1 was observed after 5 minutes of activation; activity reached a sharp maximum (5-fold activation) at 10 minutes and declined to the control levels after 20 minutes of incubation. Intracellular cAMP concentrations exhibited a similar time and dose response, reaching a maximum (0.767Ϯ0.047 fmol/10 3 cells; meanϮSEM) at 10 minutes for 100 nmol/L ET-1, with control values of intracellular cAMP Figure 1 . Effects of ET-1 on PAI-1 and t-PA production by CNS-EC. A, Subconfluent cultures of CNS EC were treated with 30 nmol/L or 100 nmol/L ET-1. After 72 hours the supernatants were collected and analyzed for PAI-1 protein with ELISA. The results are presented as the ratio of PAI-1 concentrations in the stimulated culture supernatants relative to the supernatants of control untreated cells. B, Subconfluent cultures were treated with ET-1 (100 nmol/L) for 1, 3, 6, or 24 hours. Total RNA was isolated from the differently treated groups and probed with 32 Plabeled PAI-1 and ␤-actin riboprobes using RPA. The specific bands for PAI-1 and ␤-actin were visualized using autoradiography. The bands were identified by their appropriate sizes (PAI-1, 614 bp; ␤-actin, 320 bp). C, Cells were treated with ET-1 (100 nmol/L), TNF-␣ (10 mg/mL), or both reagents for 72 hours as described above. Supernatants were tested for t-PA protein by ELISA. The data are presented as ratios of treated versus control supernatants as described above.
at 0.327Ϯ0.031 fmol/10 3 cells (meanϮSEM). The addition of forskolin and dBu-cAMP was routinely used as a positive control for both PK-A activity and cAMP elevation. These data demonstrate that ET-1, as with most reported PK-A activators, activates PK-A via increased intracellular cAMP concentrations.
ET-1 Increases PK-C Activity in CNS EC
The time course of the effect of 100 nmol/L ET-1 on membrane PK-C activity in CNS EC is shown in Figure 6 . The increase in PK-C activity was significant at 2 minutes, reached a maximum at 10 minutes, sharply decreased by 20 minutes, and thereafter slowly declined to the longest observed time of 60 minutes, when the activity was still above the control levels ( Figure 6 ). Because ET-1 activated both PK-A and PK-C in CNS EC, we used the cAMP-elevating agents forskolin or dBu-cAMP, or the PK-C-activating agent PMA to test the effects of activation of these signal transduction pathways on PAI-1 secretion. Figure 7A shows that both forskolin and dBu-cAMP dramatically decreased PAI-1 production, whereas activation of PK-C by PMA resulted in a 2.5-fold increase in PAI-1 production. A combination of both dBu-cAMP and PMA, although attenuating the effect of PMA alone, resulted in an approximately 2-fold increase in PAI-1 production relative to the control ( Figure 7A) , thus mimicking the effect of ET-1 on the CNS EC. The role of PK-C activation in ET-1-induced PAI-1 production was established by the use of the specific PK-C inhibitor, GF. CNS EC exposed to GF for 48 hours demonstrated a marked reduction in constitutive as well as ET-induced PAI-1 production ( Figure 7B ). Cells treated with GF for 48 hours were viable as measured by the trypan blue dye exclusion assay (Ͼ90%), and produced control levels of the chemokine IL-8 (data not shown), suggesting that the treated cells were alive and functional. These results demonstrated that ET-1 stimulation of PAI-1 is mediated through the PK-C-dependent signaling pathway.
Discussion
This work was initiated to examine the effect of ET-1 on the coagulation activity of human CNS EC, and to identify the intracellular signal transduction pathways responsible for this effect. The regulation of PAI-1 secretion by ET-1 appears to be a complex process, which will be best discussed by separating it into different parts, because there is no agreement in the literature on such important questions as the effect of ET-1 on PAI-1 or t-PA production, the effect of ET-1 on intracellular cAMP level, and the effect of increasing cAMP or PK-C activation on the production of PAI-1. First, there is no agreement in the literature on the effect of ET-1 on PAI-1 production. Previous studies of the effects of ET-1 on t-PA and PAI-1 production by EC failed to detect ET-1-induced increase in PAI-1 production. Yamamoto et al 42 found that ET-1 did not affect PAI-1 released from human umbilical vein endothelial cells (HUVEC), but suppressed thrombin-induced release of PAI-1 from HUVEC, and only at high concentrations of both thrombin and ET-1. Yamamoto et al 42 thus suggested that ET-1 may serve as an anti-fibrinolytic factor when EC-mediated fibrinolysis is stimulated by thrombin; they also suggested that both vasoconstriction and reduction of fibrinolysis are physiological roles of ET-1. This group also reported that although 100 nmol/L ET-1 did not affect PAI-1 secretion from HUVEC in 24 hours of incubation, it significantly attenuated the TNF-␣-induced increase. A lack of effect of ET-1 (10 nmol/L, 24 hours) on basal t-PA or PAI-1 production by HUVEC was also reported by Rydholm et al. 43 ET-1-induced PAI-1 increase was reported not in EC, but in rat mesangial cells by Iwamoto et al. 44 This discrepancy may be because of the duration of the treatment with ET-1. In agreement with the results of Yamamoto et al 42 and Rydholm et al, 43 we have also observed no significant increase of PAI-1 production induced by ET-1 in 24 hours; however a significant effect was achieved at the 48-hour time, with further increase relative to the control at 72 hours in the continuous presence of the peptide. Furthermore, we demonstrated an ET-1-induced increase in PAI-1 activity, which correlated with increased PAI-1 secretion, and no apparent effect on t-PA production.
Our results on the synergistic effect of low ET-1 and TNF-␣ concentrations to increase PAI-1 production by CNS EC are, however, in sharp disagreement with the observations of others 42 who reported the attenuation of the PAI-1-increasing effect of TNF-␣ by ET-1 in HUVEC. One possible reason for the discrepancy between our results and those above may be because of the different types of EC used: Yamamoto et al 42 used HUVEC, systemic-derived macrovessels, compared with CNS-derived microvascular cells, which are functionally different. [45] [46] [47] For example, coagulation factors, eg, thrombin, stimulate EC from large vessels but not from the capillaries 48 ; elevation of glucose resulted in decreased PAI-1 mRNA in brain EC, but not in HUVEC 49 ; PMA suppressed the basic fibroblast growth factor-induced proliferation of capillary EC, but had no effect on aortic EC 50 ; and vanadate treatment inhibited protein tyrosine kinase activity in aortic EC, but not capillary EC. 51 Thus, these EC differ not only in the array of growth factor receptors present on their surfaces, but also in their intracellular regulatory mechanisms. The mechanism of the synergistic effects of TNF-␣ and ET-1 are not known, and may be attributed to several pathways. TNF-␣ may act indirectly through products of arachidonic acid metabolism or directly through intracellular enzymatic mediators (eg, protein tyrosine kinase). These processes are currently under investigation in this laboratory.
In the present work we found that ET-1 activates both PK-C-and cAMP-dependent signal transduction pathways. Again, there is no agreement in the literature regarding the effects of ET-1 on intracellular cAMP levels or PK-C activity. The effects of ET-1 on intracellular cAMP levels appear to be cell type-dependent, possibly related to coupling of ET A and ET B receptors to adenylyl cyclases via different G-proteins. 52, 53 Thus, ET-1 inhibits activator-induced cAMP increase in bovine EC, 52 astrocytes, 54 rat glioma cells, 55 Swiss 3T3 cells, 56 pig granulosa cells, 57 and in rat nephron segments. 58 ET-1-induced elevation of cAMP was observed in platelets. 59 A small to negligible increase of cAMP by ET-1 was observed in rat glomerular mesangial cells, 60 vascular smooth muscle cells, 61 and intact preparations of rabbit aorta 62 and atria. 63 Ladoux and Frelin 21 reported that in rat CNS EC, ET-1 inhibits cholera-toxin-induced increase in cAMP, whereas Stanimirovic et al 64 have shown that in human CNS EC, ET-1 increases intracellular cAMP. Inhibi- tion of cAMP was previously associated with ET B receptors, 52, 53 and it was indeed thought that EC primarily possess this receptor type. 15, 16 Our results agree with those of Stanimirovic et al 18 and are consistent with the presence of ET A receptors on human CNS EC.
Most studies, including the present work, associate an increase in intracellular cAMP levels with a decrease in PAI-1 production. Studying the effect of intracellular cAMP levels on PAI-1 production, Slivka and Loskutoff 65 showed that elevation of cAMP by forskolin and phosphodiesterase inhibitor 3-isobutyl-1-methyl-xanthene (IBMX) decreases PAI synthesis by bovine aortic EC. Rydholm et al 43 also found that forskolin decreases PAI-1 production by HUVEC to 61% of control, as compared with Ͻ40% of the control observed by us for the effect of forskolin or dBu-cAMP ( Figure 7A ). Santell and Levin 39 and Francis and Neely 66 also reported that cAMP-elevating agents inhibited the PAI-1 synthesis in HUVEC. In contrast, only a small effect of forskolin and dBu-cAMP on PAI-1 production by HUVEC was found by Fukao et al. 67 Thus, the elevation of cAMP by ET-1 or TNF-␣ observed in the present and previous studies cannot explain the increased PAI-1 production.
In addition to activation of PK-A, our data showed that ET-1 activated PK-C in CNS EC, agreeing with the results from other laboratories using various cell types. ET-1-induced release of inositol 1,4,5-triphosphate, which is an indication of the activity of phospholipase C, and generation of PK-C-activating diacylglycerol was reported in rat CNS EC by Stanimirovic et al. 64 In both smooth muscle cells and fibroblasts, ET-1 rapidly stimulated a biphasic increase in diacylglycerol that was sustained for 20 minutes or longer. 68 ET-1 stimulated rapid phosphatidylcholine breakdown in Rat-1 fibroblasts 69 and stimulated phospholipase C in Swiss 3T3 cells 56 and in rat vascular smooth muscle cells leading to PK-C activation. 70 ET-1-induced PK-C activation was also observed in rat aortic rings 71 and in rat cardiomyocyte preparations. 72 Activation of PK-C by TNF-␣ was also demonstrated in several cell lines, including human EC cell line EA.hy 926, HUVEC, and human leukemic cell lines, [73] [74] [75] agreeing with our observations on human CNS EC. In addition, direct measurements of PK-C activation of CNS EC at 10 minutes with TNF-␣ have demonstrated increased PK-C activity (Zidovetzki et al, unpublished observation, 1996). However, no effect of TNF-␣ on PK-C activity on HUVEC was reported by Ritchie et al. 76 Mattila et al 74 explained the lack of PK-C activation by TNF-␣ reported in some studies by the observation that PK-C activity was measured at irrelevant times.
In a number of studies, activation of PK-C by PMA or other agents was associated with increased PAI-1 production in various EC, including HUVEC, 9, 43, 77 bovine CNS EC, 49 bovine aortic EC, 49, 65 and human CNS EC (this study). Thus, most of the observations in this and previous studies indicate that elevated cAMP is associated with a decrease, and activation of PK-C with an increase, in PAI-1 production. Moreover, Santell and Levin 39 have found that PMA-induced PAI-1 synthesis was prevented by elevation of cAMP. Nevertheless, Santell and Levin concluded that activation of cAMP in HUVEC, in coordination with PMA, led to a profibrinolytic state in EC. A synergistic decrease of PAI-1 production by PMA and forskolin was reported by Sitter et al. 78 Our results in CNS EC subjected to both PK-C activation by PMA and an increase in cAMP by dBu-cAMP partially agree with the results of Santell and Levin, 39 and support their conclusion. In our system, dBu-cAMP attenuated PMAinduced PAI-1 production by CNS EC from 254Ϯ17% to 212Ϯ15%; thus the combination of both agents still resulted in a significantly higher PAI-1 production relative to the control ( Figure 7A ).
In conclusion, these findings acknowledge the role of ET-1 in regulating hemostasis activity in CNS EC; and further indicate that activation of PK-C is required for ET-1-induced increase in PAI-1 production by human CNS EC. With this information, the development of potent ET receptor antagonists or the use of specific signal pathway inhibitors may provide the tools necessary to study ET in cerebral ischemia and provide novel therapeutic approaches.
